VanEck Pharmaceutical ETF
138 hedge funds and large institutions have $417M invested in VanEck Pharmaceutical ETF in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 9 closing their positions.
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
227% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $499K
25% more funds holding
Funds holding: 110 → 138 (+28)
18% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 34
8% more capital invested
Capital invested by funds: $387M → $417M (+$30.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.91% less ownership
Funds ownership: 87.37% → 77.47% (-9.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSAM
J. Safra Asset Management
New York
|
+$6.09M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.58M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.27M |
| 4 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
+$3.09M |
| 5 |
Jane Street
New York
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$19M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$8.76M |
| 3 |
VV
Verity & Verity
Beaufort,
South Carolina
|
-$7.77M |
| 4 |
VAS
Valicenti Advisory Services
Elmira,
New York
|
-$4.96M |
| 5 |
JP Morgan Chase
New York
|
-$4.52M |
PPH Hedge Fund Activity: Q1 2024 in Review
138 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2024, worth a combined $417M — up 7.8% from $387M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PPH positions and 9 closed out — a net gain of 29 holders — while 40 added to existing stakes and 34 trimmed.
The largest buyer was J. Safra Asset Management, opening a new position worth an estimated $6.09M. The largest seller was Bank of America, cutting an estimated $19M.
- 138 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2024, up from 110 in Q4 2023.
- Funds reported $417M of VanEck Pharmaceutical ETF stock for Q1 2024, up 7.8% quarter-over-quarter.
- 38 funds opened new VanEck Pharmaceutical ETF positions in Q1 2024 and 9 closed out, a net change of +29 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2024 was J. Safra Asset Management, an estimated $6.09M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2024 was Bank of America, an estimated $19M sold.
Based on aggregated 13F filings for Q1 2024.